About: Tocilizumab for the treatment of severe coronavirus disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab for the treatment of severe coronavirus disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tocilizumab for the treatment of severe coronavirus disease 2019
Creator	Alsoub, Hussam Omrani, Ali Abdalla, Shiema Correspondence, Ali Omrani, Aboukamar, Mohamed Abukhattab, \| Alattar, Rand Almaslamani, Muna Daghfal, Joanne Ibrahim, B Khatib, Mohamed Shaar, Shahd Shukri, Kinda Tawheeda, \|
source	Medline; PMC
abstract	Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory‐confirmed severe COVID‐19 who received tocilizumab and completed 14 days of follow up. Twenty‐five patients were included, median age was 58 years (interquartile range, 50‐63) and the majority were males (92%). Co‐morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0°C, 37.3°C (P = .043), and 37.0°C (P = .064), respectively. Corresponding median C‐reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID‐19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.
has issue date	2020-05-10(xsd:dateTime)
bibo:doi	10.1002/jmv.25964
bibo:pmid	32369191
has license	no-cc
sha1sum (hex)	59231a3b62cd4d351a59dc9b837fb085a14d4029
schema:url	https://doi.org/10.1002/jmv.25964
resource representing a document's title	Tocilizumab for the treatment of severe coronavirus disease 2019
has PubMed Central identifier	PMC7267594
has PubMed identifier	32369191
schema:publication	J Med Virol
resource representing a document's body	covid:59231a3b62cd4d351a59dc9b837fb085a14d4029#body_text
is schema:about of	named entity 'presenting' named entity 'alive' named entity 'dyspnea' named entity 'The' named entity 'median age' named entity 'coronavirus disease 2019' named entity 'majority' named entity 'tocilizumab' named entity 'day' named entity 'proportion' named entity 'investigational' named entity 'chronic kidney disease' named entity 'Radiological' named entity 'patients' named entity 'tocilizumab' named entity 'interleukin-6' named entity 'retrospective review' named entity 'Fever' named entity 'tocilizumab' named entity 'Tocilizumab' named entity 'adverse event' named entity 'COVID' named entity 'clinical outcomes' named entity 'control arm' named entity 'critically ill' named entity 'COVID' named entity 'adverse events' named entity 'immune response' named entity 'histopathological examination' named entity 'Italy' named entity 'COVID' named entity 'tocilizumab' named entity 'infection' named entity 'Candida' named entity 'giant cell arteritis' named entity 'juvenile idiopathic arthritis' named entity 'tocilizumab' named entity 'COVID' named entity 'co-morbidities' named entity 'ICU' named entity 'IL-6' named entity 'tocilizumab' named entity 'cytokine interleukin-6' named entity 'Qatar' named entity 'therapeutic interventions' named entity 'serum' named entity 'hydroxychloroquine' named entity 'severe pneumonia' named entity 'COVID' named entity 'oral Herpes' named entity 'COVID-19' named entity 'adverse events' named entity 'invasive ventilation' named entity 'inflammatory' named entity 'rheumatoid arthritis' named entity 'lung tissue' named entity 'pneumonia' named entity 'tocilizumab' named entity 'ICU' named entity 'ICU' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'clinical characteristics' named entity 'tocilizumab' named entity 'hypoxia' named entity 'all-cause mortality' named entity 'tocilizumab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software